Scienture (NASDAQ:SCNX) Upgraded to “Hold” at Wall Street Zen

Scienture (NASDAQ:SCNX) was upgraded by analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

A number of other brokerages have also issued reports on SCNX. Maxim Group started coverage on Scienture in a research note on Tuesday, February 24th. They issued a “buy” rating and a $1.50 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Scienture has a consensus rating of “Hold” and a consensus target price of $1.50.

Scienture Price Performance

Shares of SCNX stock opened at $0.47 on Friday. The company has a market capitalization of $18.99 million, a price-to-earnings ratio of -0.47 and a beta of 3.01. Scienture has a one year low of $0.37 and a one year high of $3.17. The company’s fifty day moving average price is $0.46 and its 200-day moving average price is $0.65.

Hedge Funds Weigh In On Scienture

A hedge fund recently raised its stake in Scienture stock. Geode Capital Management LLC boosted its stake in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) by 264.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 316,201 shares of the company’s stock after acquiring an additional 229,398 shares during the period. Geode Capital Management LLC owned 0.78% of Scienture worth $161,000 at the end of the most recent quarter. 5.68% of the stock is currently owned by hedge funds and other institutional investors.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.